ACAN
AmeriCann is a producer of medical cannabis. The company maintains state of the art facilities that create controlled environments to consistently produce a high quality product. They also engage in sustainable cultivation and processing.
AmeriCann, Inc. (ACAN) is rated D+ (1.8/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (F). The rating has held at D+ for 26 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2024-09-30 | C+ (2.5) | F (0.1) | B (3.2) | D+ (1.7) | D+ (1.5) | D+ (1.8) |
| 2024-06-30 | C+ (2.5) | F (0.2) | C+ (2.5) | D+ (1.7) | D (1.5) | D+ (1.7) |
| 2024-03-31 | C+ (2.5) | D- (0.7) | D+ (1.8) | D+ (1.7) | D+ (1.5) | D+ (1.7) |
| 2023-12-31 | C+ (2.5) | D- (0.9) | C+ (2.5) | C (2.2) | D (1.5) | C- (1.9) |
| 2023-09-30 | C+ (2.5) | F (0.6) | B (3.4) | C (2.2) | D (1.5) | C- (2.0) |